NCT07194980 2026-04-20
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Not yet recruiting
Clinical Trials
7 trialsNCT07526597 2026-04-13
STOP-CLL-DCT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07508995 2026-04-03
A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07024706 2026-01-21
MAVRiC
AstraZeneca
Phase 2 Not yet recruiting
NCT06862323 2025-06-13
Time Restricted Eating in Haematological Malignancies
British Columbia Cancer Agency
Phase 2 Not yet recruiting
NCT07003464 2025-06-04
Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
The First Hospital of Jilin University
Phase 2 Not yet recruiting
NCT06367374 2024-04-16
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting